These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 7518204)

  • 1. The effect of immunosuppressants on human leukocyte NADPH oxidase.
    Engelbrecht ME; Oosthuizen MM; Myburgh JA
    Ann N Y Acad Sci; 1994 Jun; 723():436-8. PubMed ID: 7518204
    [No Abstract]   [Full Text] [Related]  

  • 2. [Mechanism of action of the new immunosuppressants: cyclosporin A, FK 506 and rapamycin].
    Rondeau E
    Nephrologie; 1992; 13(3):137. PubMed ID: 1379348
    [No Abstract]   [Full Text] [Related]  

  • 3. The spectrum of action of new immunosuppressive drugs.
    Thomson AW
    Clin Exp Immunol; 1992 Aug; 89(2):170-3. PubMed ID: 1379130
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunopharmacology of new xenobiotic immunosuppressive molecules.
    Morris RE
    Semin Nephrol; 1992 Jul; 12(4):304-14. PubMed ID: 1384096
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of treatment with cyclosporine, FK 506, rapamycin, mycophenolic acid, or deoxyspergualin on vascular muscle proliferation in vitro and in vivo.
    Gregory CR; Pratt RE; Huie P; Shorthouse R; Dzau VJ; Billingham ME; Morris RE
    Transplant Proc; 1993 Feb; 25(1 Pt 1):770-1. PubMed ID: 7679842
    [No Abstract]   [Full Text] [Related]  

  • 6. Mechanisms of action of immunosuppressive agents: cyclosporin A, FK506, and rapamycin.
    Bierer BE
    Proc Assoc Am Physicians; 1995 Apr; 107(1):28-40. PubMed ID: 8630742
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunosuppressive agents: recent developments in molecular action and clinical application.
    Gerber DA; Bonham CA; Thomson AW
    Transplant Proc; 1998 Jun; 30(4):1573-9. PubMed ID: 9636637
    [No Abstract]   [Full Text] [Related]  

  • 8. [New immunosuppressive drugs in transplantation].
    Surdacka E; Sułowicz W; Surdacki A
    Przegl Lek; 1994; 51(8):347-54. PubMed ID: 7532870
    [No Abstract]   [Full Text] [Related]  

  • 9. Combined immunosuppressive effect of FK 506 and other immunosuppressive agents on PHA- and CD3-stimulated human lymphocyte proliferation in vitro.
    Jiang H; Suguo H; Takahara S; Takano Y; Li D; Kameoka H; Moutabarrik A; Kokado Y; Ishibashi M; Okuyama A
    Transplant Proc; 1991 Dec; 23(6):2933-6. PubMed ID: 1721317
    [No Abstract]   [Full Text] [Related]  

  • 10. Modes of action of FK506, cyclosporin A, and rapamycin.
    Morris R
    Transplant Proc; 1994 Dec; 26(6):3272-5. PubMed ID: 7527964
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of the influence of FK 506, rapamycin, and cyclosporine on processing and presentation of particulate antigen by macrophages: assessment of a drug "carry-over" effect.
    Cooper MH; Gregory SH; Thomson AW; Fung JJ; Starzl TE; Wing EJ
    Transplant Proc; 1991 Dec; 23(6):2957-8. PubMed ID: 1721326
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of immunosuppressive drugs (CsA, FK 506, rapamycin) on the kidney microsomal cytochrome P-450 system in the rat.
    Yoshimura R; Yoshimura N; Ohmachi T; Nakatani T; Ohyama A; Miyao Y; Yamamoto K; Kishimoto T
    Transplant Proc; 1994 Oct; 26(5):2890. PubMed ID: 7524223
    [No Abstract]   [Full Text] [Related]  

  • 13. In vivo immunopharmacology of the macrolides FK 506 and rapamycin: toward the era of rational immunosuppressive drug discovery, development, and use.
    Morris RE
    Transplant Proc; 1991 Dec; 23(6):2722-4. PubMed ID: 1721257
    [No Abstract]   [Full Text] [Related]  

  • 14. The effects of FK 506, cyclosporine, and rapamycin on liver growth in vitro and in vivo.
    Francavilla A; Starzl TE; Carr B; Azzarone A; Carrieri G; Zeng QH; Porter KA
    Transplant Proc; 1991 Dec; 23(6):2817-20. PubMed ID: 1721287
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy of various immunosuppressive drugs in preventing pig-to-rat islet xenograft rejection.
    Wennberg L; Wallgren AC; Karlsson-Parra A; Kozlowski T; Sundberg B; Tibell A; Groth CG; Korsgren O
    Transplant Proc; 1995 Feb; 27(1):266-7. PubMed ID: 7533391
    [No Abstract]   [Full Text] [Related]  

  • 16. FK 506, rapamycin, and cyclosporine: effects on IL-4 and IL-10 mRNA levels in a T-helper 2 cell line.
    Wang SC; Zeevi A; Jordan ML; Simmons RL; Tweardy DJ
    Transplant Proc; 1991 Dec; 23(6):2920-2. PubMed ID: 1721312
    [No Abstract]   [Full Text] [Related]  

  • 17. FK 506 and rapamycin do not affect platelet aggregation or mitochondrial function.
    Pelekanou V; Trezise AE; Moore AL; Kay JE
    Transplant Proc; 1991 Dec; 23(6):3200-1. PubMed ID: 1721408
    [No Abstract]   [Full Text] [Related]  

  • 18. NADPH oxidase activity in the monocytes and neutrophils of patients with rheumatic fever.
    Kumar V; Ganguly NK; Anand IS; Wahi PL
    Cardioscience; 1991 Jun; 2(2):93-7. PubMed ID: 1878489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycophenolate acid inhibits endothelial NAD(P)H oxidase activity and superoxide formation by a Rac1-dependent mechanism.
    Krötz F; Keller M; Derflinger S; Schmid H; Gloe T; Bassermann F; Duyster J; Cohen CD; Schuhmann C; Klauss V; Pohl U; Stempfle HU; Sohn HY
    Hypertension; 2007 Jan; 49(1):201-8. PubMed ID: 17101842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapamycin inhibits spontaneous and fibroblast growth factor beta-stimulated proliferation of endothelial cells and fibroblasts.
    Akselband Y; Harding MW; Nelson PA
    Transplant Proc; 1991 Dec; 23(6):2833-6. PubMed ID: 1721292
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.